The UAE Ministry of Health and Prevention will introduce a new medicine for Type 2 diabetes which will be administered through a small titanium device the size of a matchstick that will be placed under the skin to dispense a daily dose for the diabetes patient for up to six months. The device will be available within the next 3 months.
Current data explains how similar class of medicines approved by the Food and Drug Administration in the US work: Type II diabetics tend to eat a little more than normal due to an impairment in the production of Glucagon Like Peptide I (GLP 1), a hormone produced in the small intestine which sends the signal of fullness to the brain and also sends a signal for the pancreas to release insulin after a meal. However, in diabetics, the small intestine does not produce enough GLP I and there is a delayed signal of satiety resulting in obesity which in turn leads to diabetes.
These class of medicines release GLP I for six months as per the patient’s requirement so that he eats less and thereby has better blood sugar control. But the patient will be required to take his regular medication or insulin injection along with it.
Source Credit: Khaleej Times
Read full story: http://bit.ly/2z03ZmT